Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.

Keywords

Lenalidomide, Medicine, Multiple myeloma, Dexamethasone, Internal medicine

References

• Phase III trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed multiple myeloma (E4A03): A trial coordinated by the Eastern Cooperative Oncology GroupS. Vincent Rajkumar, Susanna Jacobus, Natalie S. Callander — 2007
• Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis.Jeffrey A. Zonder, Bart Barlogie, Brian G.M. Durie — 2006
• CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATIONJoan Bladé, Diana Samson, Donna Reece — 1998
• A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma.Paul G. Richardson, Emily Blood, Constantine S. Mitsiades — 2006
• A phase 2 study of bortezomib in relapsed, refractory myeloma.Paul G. Richardson, Bart Barlogie, James R. Berenson — 2003
• Combination therapy with thalidomide plus dexamethasone for newly diagnosed myeloma.S. Vincent Rajkumar, Suzanne R. Hayman, Morie A. Gertz — 2002
• Thalidomide alone or with dexamethasone for previously untreated multiple myeloma.Donna Weber, Kim Rankin, Maria Gavino — 2003
• Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.Paul G. Richardson, Pieter Sonneveld, Michael W. Schuster — 2005
• Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy.Maurizio Zangari, Elias Anaissie, Bart Barlogie — 2001
• Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.Teru Hideshima, Dharminder Chauhan, Yoshihito Shima — 2000
• Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.Paul G. Richardson, Robert Schlossman, Edie Weller — 2002
• Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.S. Vincent Rajkumar, Suzanne R. Hayman, Martha Q. Lacy — 2005
• Antitumor activity of thalidomide in refractory multiple myeloma.Seema Singhal, Jayesh Mehta, Raman Desikan — 1999

Cited by

• Molecular profiling in multiple myelomaAnnemiek Broyl — 2012
• Investigation of the intrinsic mechanism of drug resistance in multiple myelomaMelissa Ooi — 2011
• Progress in multiple myeloma.S. Jagannath — 2008
• Novel agents in myeloma: An exciting sagaJohn Fraser-Robinson, Pip Mosscrop — 2009
• Multiple myeloma: Vague symptoms can challenge diagnostic skillsSofie Fransson, Maria Andersson — 2008
• Multiple myeloma: management of adverse events周介 小畑, 高治 森下 — 2010
• Integrating novel agents into multiple myeloma treatment - current status in Switzerland and treatment recommendations.María Milagros Cavada Nieto, Óscar Núñez García — 2010
• Immunomodulating antibodies and drugs for the treatment of hematological malignanciesRoch Houot, Holbrook E. Kohrt, Matthew J. Goldstein — 2011
• Lenalidomide treatment for patients with multiple myeloma: Diagnosis and management of most frequent adverse eventsАтаев Мурад Реджепдурдыевич — 2011
• Genomic stratification of multiple myeloma treated with novel agentsAllan Jiang, Donna Reece, Hong Chang — 2012
• Recent Advances in the Pathogenesis and Management of Cast Nephropathy (Myeloma Kidney)Muhammad Shabir, Muhammad Sohail Iqbal — 2011
• Extramedullary plasmacytomas in the context of multiple myelomaConstanza Obando Tobón, Gina María Cardona García — 2011
• Angiogenesis: a target in solid tumors, also in leukemia?Jaime Alvarez — 2011
• Bench-to-bedside translation of targeted therapies in multiple myelomaNichole C. Bauer — 2012
• The role of natural killer cells in immunity against multiple myelomaJames Godfrey, Don M. Benson — 2012
• Lenalidomide before and after Autologous Hematopoietic Stem Cell Transplantation in Multiple MyelomaВан Хааске Леонид Андреевич — 2012
• Matched-pair analysis to compare the outcomes of a second salvage auto-SCT to systemic chemotherapy alone in patients with multiple myeloma who relapsed after front-line auto-SCTDouglas B. Jackson‐Smith — 2013
• Efficacy and safety of lenalidomide in patients with myelodysplastic syndrome with chromosome 5q deletionShueb Sultan — 2012
• The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: Final results on 205 patients of the Greek myeloma study group知子 城田, 京子 野田 — 2014
• Can CRd be a standard for refractory myeloma?David J. Darling — 2013

Related papers

• Comparison of Two Therapeutic Regimes, Lenalidomide with Dexamethasone and Thalidomide with Dexamethasone, in the Treatment of Multiple Myeloma at a Tertiary Care Hospital in India.Nithin Sashidharan — 2015
• CEP-18770 (delanzomib) in combination with dexamethasone and lenalidomide inhibits the growth of multiple myeloma.Eric Sanchez, Mingjie Li, Jennifer Li — 2012
• [The use of lenalidomide in the treatment of multiple myeloma].Miloš Holánek, Roman Hájek — 2010
• Dexamethasone plus lenalidomide in treatment of multiple myelomaDeng Wei, Ya Mingxi, Jian-Wang Xu — 2011
• Single agent lenalidomide in newly diagnosed multiple myeloma: a retrospective analysisRachid Baz, Mehul Patel, Elizabeth Finley-Oliver — 2010
• Induction by lenalidomide and dexamethasone combination increases regulatory cells of patients with previously untreated multiple myelomaKarthick Raja Muthu Raja, Lucie Kovářová, Roman Hájek — 2012
• Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.A. Keith Stewart, S. Vincent Rajkumar, Meletios Α. Dimopoulos — 2015